Trials / Recruiting
RecruitingNCT07029581
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- ACADIA Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 55 Years – 84 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACP-204 | Provided as 1 capsule, to be taken orally once daily |
| DRUG | Placebo | Provided as 1 capsule, to be taken orally once daily |
Timeline
- Start date
- 2025-08-06
- Primary completion
- 2028-02-01
- Completion
- 2028-03-01
- First posted
- 2025-06-19
- Last updated
- 2026-03-24
Locations
52 sites across 6 countries: United States, Bulgaria, Czechia, France, Italy, Serbia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07029581. Inclusion in this directory is not an endorsement.